triheptanoin   Click here for help

GtoPdb Ligand ID: 11431

Synonyms: Dojolvi® | UX-007 | UX007
Approved drug
triheptanoin is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Triheptanoin is a medium-chain triglyceride that is administered as a rescue therapeutic in patients with long-chain fatty acid oxidation disorders [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 23
Topological polar surface area 78.9
Molecular weight 428.31
XLogP 7.93
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCC(=O)OC(COC(=O)CCCCCC)COC(=O)CCCCCC
Isomeric SMILES CCCCCCC(=O)OC(COC(=O)CCCCCC)COC(=O)CCCCCC
InChI InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3
InChI Key PJHKBYALYHRYSK-UHFFFAOYSA-N
References
1. Shirley M. (2020)
Triheptanoin: First Approval.
Drugs, 80 (15): 1595-1600. [PMID:32897506]
2. Vockley J, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman K, Tanpaiboon P, Grunewald S, Murphy E et al.. (2021)
Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
J Inherit Metab Dis, 44 (1): 253-263. [PMID:32885845]
3. Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Bowden A et al.. (2019)
Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).
J Inherit Metab Dis, 42 (1): 169-177. [PMID:30740733]